C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 5, 2013, Pages 1034-1039

  Franceschini, Christian ^a   Trapella, Claudio ^a   Calia, Rosaria ^a   Scotti, Alessandra ^a   Sforza, Fabio ^a   Gavioli, Riccardo ^a   Marastoni, Mauro ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Caspase like inhibition; Muconic acid; Proteasome; Retro inverso peptides

Indexed keywords

CASPASE; ESTER DERIVATIVE; MUCONIC ACID ETHYL ESTER; PARTIAL RETRO INVERSO PSEUDOPEPTIDE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; BETA 1 SUBUNIT; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE;

DOSE-RESPONSE RELATIONSHIP, DRUG; ESTERS; MOLECULAR STRUCTURE; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SORBIC ACID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884255571     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.709241     Document Type: Article

References (30)

1. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: The ubiquitin connection. Ann Intern Med 2006;145:676-684.
2. McGrath JP, Jentsch S, Varshavsky A. UBA 1: An essential yeast gene encoding ubiquitin-activating enzyme. EMBO J 1991;10:227-236.
3. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463-471.
4. Groll M, Bajorek M, Köhler A, Moroder L, Rubin DM, Huber R et al. A gated channel into the proteasome core particle. Nat Struct Biol 2000;7:1062-1067.
5. Navon A, Goldberg AL. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol Cell 2001;8:1339-1349.
6. Groll M, Heinemeyer W, Jäger S, Ullrich T, Bochtler M, Wolf DH et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study. Proc Natl Acad Sci USA 1999;96:10976-10983.
7. Borissenko L, Groll M. 20S proteasome and its inhibitors: Crystallographic knowledge for drug development. Chem Rev 2007;107:687-717.
8. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007;35:12-17.
9. Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M et al. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol 2009;16:1278-1289.
10. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-758.
11. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol 2008;15:501-512.
12. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-421.
13. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391.
14. Nazif T, Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci USA 2001;98:2967-2972.
15. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731.
16. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006;128:5136-5141.
17. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008;452:755-758.
18. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: An expanding army attacking a unique target. Chem Biol 2012;19:99-115.
19. Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 2009;15:58-66.
20. Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: Recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010;10:232-256.
21. Kohno J, Koguchi Y, Nishio M, Nakao K, Kuroda M, Shimizu R et al. Structures of TMC-95A-D: Novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J Org Chem 2000;65:990-995.
22. Marastoni M, Baldisserotto A, Canella A, Gavioli R, Risi CD, Pollini GP et al. Arecoline tripeptide inhibitors of proteasome. J Med Chem 2004;47:1587-1590.
23. Marastoni M, Baldisserotto A, Trapella C, Gavioli R, Tomatis R. P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors. Bioorg Med Chem Lett 2006;16:3125-3130.
24. Baldisserotto A, Ferretti V, Destro F, Franceschini C, Marastoni M, Gavioli R et al. Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: New proteasome inhibitors. J Med Chem 2010;53:6511-6515.
25. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: Science and market. Drug Discov Today 2010;15:40-56.
26. Chorev M. The partial retro-inverso modification: A road traveled together. Biopolymers 2005;80:67-84.
27. Pallai P, Goodman M. Preparation of optically pure monoacyl 2-alkyl gem-diamines from peptide amides. J Chem: Soc Chem Commun 1982;5:280-281.
28. Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein- Barr virus-associated tumors. Int J Cancer 2002;101:532-538.
29. Marastoni M, Baldisserotto A, Cellini S, Gavioli R, Tomatis R. Peptidyl vinyl ester derivatives: New class of selective inhibitors of proteasome trypsin-like activity. J Med Chem 2005;48:5038-5042.
30. Lei B, Abdul Hameed MD, Hamza A, Wehenkel M, Muzyka JL, Yao XJ et al. Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. J Phys Chem B 2010;114:12333-12339.